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Parametric exploration of the liver by magnetic
resonance methods
Abstract MRI, as a completely non-
invasive technique, can provide
quantitative assessment of perfusion,
diffusion, viscoelasticity and metabo-
lism, yielding diverse information
about liver function. Furthermore,
pathological accumulations of iron
and lipids can be quantified. Perfusion
MRI with various contrast agents is
commonly used for the detection and
characterization of focal liver disease
and the quantification of blood flow
parameters. An extended new
application is the evaluation of the
therapeutic effect of antiangiogenic
drugs on liver tumours. Novel, but
already widespread, is a histologically
validated relaxometry method using
five gradient echo sequences for
quantifying liver iron content eleva-
tion, a measure of inflammation, liver
disease and cancer. Because of the
high perfusion fraction in the liver, the
apparent diffusion coefficients
strongly depend on the gradient
factors used in diffusion-weighted
MRI. While complicating analysis,
this offers the opportunity to study
perfusion without contrast injection.
Another novel method, MR elasto-
graphy, has already been established
as the only technique able to stage
fibrosis or diagnose mild disease. Liver
fat content is accurately determined
with multivoxel MR spectroscopy
(MRS) or by faster MRI methods that
are, despite their widespread use, prone
to systematic error. Focal liver disease
characterisation will be of great benefit
once multivoxel methods with fat
suppression are implemented in proton
MRS, in particular on high-field MR
systems providing gains in signal-
to-noise ratio and spectral resolution.
Keywords Magnetic resonance
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Introduction
Although hepatic MR is now widely performed, it is still
mainly used to detect focal lesions. However it is becoming
much more widely appreciated that MR can provide a wide
range of information about hepatic function and clinicians
are beginning to request such investigations. Hence a
review article is considered timely in order to familiarise
more general radiologists about what MR can now offer.
Perfusion
The liver is supplied with blood by the portal vein (75%)
and by the hepatic artery (25%). Hepatic perfusion disorder
refers to perfusion differences among segments, subseg-
ments and lobes of the liver caused by various aetiologies,
such as portal vein obstruction, liver cirrhosis, hepatic
neoplasms, hepatic trauma, hereditary haemorrhagic telan-
giectasia, hepatic vein obstruction, steal phenomenon by
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Fax: +31-50-3611798hypervascular tumours, inflammatory changes, aberrant
blood supply and hepatic parenchymal compression [1, 2].
MRI contrast agents are intended to improve lesion
detection and characterisation by increasing liver–lesion
contrast. These agents include nonspecific extracellular
gadolinium (Gd) chelates, reticuloendothelial system-
specific (RES) iron oxides and hepatocyte-selective agents
[3]. All contrast agents used in MRI of the liver display
their effect by decreasing T1 relaxation times (Gd and
manganese [Mn]) and T2 relaxation times of liver paren-
chyma (superparamagnetic iron oxides). After extracellular
contrast agent has been injected, the liver is imaged in the
hepatic artery (18–20 s delay), portal vein (45–60 s) and
interstitial (1.5–5 min) phases, and it can be characterised
by the enhancement pattern during these phases and the
differences between the degree and duration of enhance-
ment and washout [3]. During the hepatic arterial dominant
phase haemangiomas, metastases and hepatocellular carci-
nomas show heterogeneous enhancement, while adenomas
and focal nodular hyperplasia are enhanced uniformly. In
the portal vein phase the liver signals are very intense,
whereas the other structures show delayed enhancement
and washout phenomena. Reticuloendothelial system-
specific contrast agents contain iron oxide particles and
they affect RES cells, receptors in cell walls or the blood
pool, leading to signal loss in normal liver parenchyma as
observed in T2*- and T2-weighted sequences. RES-
specific contrast is frequently used in MR angiography.
Hepatocyte-selective, Mn-containing contrast agents, taken
up by hepatocytes and eliminated through bile, reveal
nonenhancing lesions such as haemangiomas, metastases,
cholangiocarcinomas and lymphomas.
Up to now quantitative perfusion MRI studies of the
liver have mainly focused on tissue characterisation with
Gd contrast, using the hepatic perfusion index (HPI), mean
transit time (MTT), distribution volume (DV), total blood
flow (Ft), arterial blood flow (Fa) and portal blood flow
(Fp) as parameters. It was reported that the values of Ft, Fa,
Fp and DV are significantly higher in hepatocellular
carcinoma than in liver metastases of colorectal cancer,
whereas MTT is higher in the metastases [4]. The largest
and most significant difference between hepatocellular
carcinoma and colorectal metastatic cancer was that in Fp:
8.1 vs. 0.03 mL/min/g (median values; p=0.0001). The
example in Fig. 1 illustrates that in hepatocellular carcino-
ma and in colorectal metastases total blood flow is,
respectively, higher and lower than in normal liver tissue
[4]. In hepatic metastases the HPI, initially elevated
compared with the whole liver (0.75±14 vs. 0.66±0.16;
p<0.01), was shown to decrease by 15% (P<0.05) after
treatment with an antiangiogenic compound [5]. This
opens up the therapeutic monitoring of antiangiogenic
drugs in liver tumours as a promising new application of
perfusion-weighted MRI. In patients with advanced liver
fibrosis Fa and MTT were about three times as large as in
controls (p<0.01, in both cases) [6]. It is concluded that the
use of contrast-enhanced MRI for the noninvasive diagno-
sis of hepatocellular carcinoma can make an important
contribution to patient prognosis, and in the identification
and characterisation of liver lesions such as distinguishing
between malignant and benign lesions. Although, cur-
rently, combined use of contrast-enhanced spiral CT in
arterial phase and portal phase is considered the most
sensitive imaging technique [2] and contrast-enhanced
ultrasonography also remains a good alternative to con-
trast-enhanced MRI [7], MRI with specific contrast
enhancement may offer more relevant information on
hepatic perfusion abnormalities.
Iron content
Ferritin concentration in plasma reflects the amount of
ferritin, the iron storage molecule in the human body,
within body cells and has thus been used for decades as a
diagnostic indicator of the iron concentration in the liver
[8]. This measure of the size of iron stores in the liver is a
key parameter in the management of haemochromatosis
and other diseases associated with iron overload and an

































































Fig. 1 Signal intensity vs. time curves of the liver, aorta, portal vein
and nodule a in a man with hepatocellular carcinoma (the total blood
flow is higher in the hypervascular tumour than in the liver
parenchyma) and b in a woman with colorectal metastatic cancer
(the total blood flow is lower in the hypovascular metastasis than in
normal liver) (reproduced with permission from Abdullah et al. [4])
2595disorders including cancer and cardiovascular diseases.
The most common cause of an elevated plasma ferritin
level other than an increase in iron stores per se is
inflammation. In inflammation, liver disease, cancer and
some other diseases, the serum ferritin concentration is
increased disproportionally to stores, suggesting an addi-
tional effect of ferritin turnover [9–11].
Iron behaves like a contrast agent with a T2* effect.
Under these conditions the concentration is proportional to
R2* (=1/T2*). In determining iron stores, MRI can replace
invasive liver biopsy, and is less influenced by coexisting
conditions than is the case with serum ferritin [12].
Different MRI protocols are available based on the
measurement of signal intensity ratios and relaxometry
techniques [13–15]. In particular, gradient-recalled echo
(GRE) sequences are accurate for the estimation of hepatic
iron concentration [16]. Obviously, in these MRI examina-
tions pre-“contrast” series are not available, so the results in
patients must be compared with those in other patients and
healthy controls. Recently, an analysis method aimed at
making the results independent of the quality of the shim
and interindividual variations was validated by biopsy in
149 patients [17]. Gandon et al. used a set of five gradient
echo sequences for determining the signal intensity values
in regions of interest located within liver and (reference)
muscle tissue to determine liver/muscle signal ratios. An
algorithm yields hepatic iron concentration by selecting the
most accurate outcome from the receiver operating char-
acteristic curve of each sequence [17]. This method applied
in 28 patients showed significant correlation with blood
plasma ferritin content (Spearman’s r=0.66; P<0.001) and
a slightly improved correlation coefficient when limited to
those patients known to not have inflammation (r=0.82;
n=17; P<0.001) [18]. Concerning haematological disease,
there was correlation between liver iron content and plasma
ferritin level (r=0.79; n=13; P=0.001). It was concluded
that in patients without inflammation and in patients with
haematological disease the content of ferritin in blood is a
better predictor of liver iron content than in other patient
categories [18]. One should be aware that serum ferritin
levels can be confounded by factors such as infection,
inflammation and malignancy, resulting in inaccurate
reflections of tissue iron concentration. In the literature,
correlations of MRI measures of liver iron content and
plasma ferritin concentration are scarcely documented. In
recent studies of thalassaemia patients, serum ferritin levels
were shown to correlate significantly with liver T2 values,
T2* values and/or with the liver-to-muscle signal ratios
[19, 20]. An example showing a significant inverse
correlation between T2* and serum ferritin is shown in
Fig. 2. Alústiza et al. [21] compared the method of Gandon
with the results of biopsies, and the results indicated a
positive argument for the reproducibility of Gandon’s
technique. Several other authors also use Gandon’s meth-
od, for example, as inclusion criteria in a trial [22]o ri na
study in patients with beta-thalassaemia [23].
At this time, the method of Gandon et al. [17] appears to
be the most suitable technique for the noninvasive
measurement of liver iron concentration in view of the
important histological correlations. Compared with an
earlier biopsy-validated method [13], inter- and intraob-
server correlations are better [24]. The enhanced accuracy
is probably the result of the automated preselection of one
of the five most sensitive sequences in the estimated liver
iron concentration range. Correlation with serum ferritin
depends on inflammation/infection parameters and on
underlying disease, reflecting the more reliable measure-
ment of body iron stores by MRI compared with serum
ferritin. The question is raised whether MRI protocols to
measure liver iron concentration can be applied to MR
systems other than that on which they are validated. The
reproducibility observed by Alústiza et al. [21] reinforces
the possibility of using this method on any 1.5-T MR
system. A limitation in Gandon’s method is that signal
measurements must be performed with the body coil,
because when using smaller coils (such as the phased-array
coil) for signal reception the reference signal intensities in
muscle signal are unreliable. The requirement of good B0
and B1 field homogeneity over the entire field of view and
field-dependent changes in relaxation behaviour should be
Fig. 2 Relationship between
liver T2* values and serum
ferritin concentrations in the
entire study population. Dashed
lines represent the reference
range for liver T2* values and
an arbitrary limit of 2,000 μg/L
for serum ferritin (n=64;
r=0.465; P<0.011) (repro-
duced with permission from
Perifanis et al. [19])
2596taken into account when adapting Gandon’s method on MR
systems of 3 T and up. All factors that influence T2*
(quality of the shim, inflammation, fibrosis, steatosis, etc.)
will affect the quality of the measure and must be taken into
account when interpreting the results.
In iron overload studies, more than 70% of body iron is
found in the liver and liver iron content has been
considered the best marker of total body iron burden
[15]. However, hepatic iron deposition measured by MRI
and serum ferritin has shown little correlation with the iron
levels in other organs, such as the pituitary gland or the
heart [15, 19]. Important decisions in, for example, the
clinical management related to cardiac risk, should there-
fore not rely on these parameters [19].
Diffusion
In the last decade, measurement of apparent diffusion
coefficient (ADC) of the water molecules through tissues
has developed into another useful tool in the characterisa-
tion of hepatic lesions and in the evaluation of diffuse liver
disease. This MRI application has no equivalent in other
diagnostic techniques. The principle is that in the presence
of magnetic field gradients, displacement of spins during
the echo time of a spin-echo sequence produces a phase
shift of the transverse magnetisation. This loss of phase
coherence in the transverse magnetisation causes a spin-
echo amplitude attenuation in addition to that created by
the spin-spin relaxation process [25]:
ST E ðÞ ¼ S 0 ðÞ B   exp  TE=T2 ðÞ (1)
in which B is equal to exp(−b·D), with b a gradient factor
depending on the gradient pulse sequence and D the
diffusion coefficient. Diffusion-weighted imaging (DWI)
wasinitiallyusedforthequalitativeassessmentoftheimpact
of a gradient applied for a certain time per area unit on echo
planar MR images. Right now, series measured with two or




the same TE in order to eliminate the T2 term). In this case
the ADC or the degree of molecular motion of water
measured on DWI is calculated as follows:
ADCb0;b1 ¼
 1






where Ib1 and Ib0 are the DW intensities measured using a
high and low b value, respectively (for instance 0 and
1,000s/mm
2).Studies onvariousorgansinthehumanbody
have shown that measured ADC values depend on the
gradient factors chosen, as at the lower end of the range
(b1<400 s/mm
2) microcirculation or perfusion tends to
increase the overall ADC value measured, whereas at
b1>400 s/mm
2 increased contributions from restricted and
compartmentalised cellular environments tend to decrease
ADC [25–27]. As a matter of fact, it has been shown that in
theliverdiffusionisnotmonoexponential[25,28].Arecent
DWI study using ten b factors running from 0 to 800 s/mm
2
indicated that the perfusion component is about 30%,
meaningthat,unlikeinthebrain,theeffectsofperfusionare
far from negligible in the liver [28]. This has enhanced the
discrepancies between liver DWI studies from institutions
using different b value sets, but also offers opportunities to
study liver perfusion without the need for contrast injection.
At this time, the latter prospect remains theoretical without
anyroutineapplicationinliverMRIuptonow.Theoptimum
bfactorsforthebestcontrastinimagingarerelatedtoTE,the
signal-to-noise ratio of the sequence, the T2 and diffusion
components of the studied structures.
Inoneclinicalstudy,inwhichthebvalueswereoptimised
for the detection and characterisation of benign and
malignant hepatic lesions, the specificities were similar for
all sequences [29]. However, the sensitivity for malignant
lesions turned out to be highest for b1=100 s/mm
2, whereas
that for benign lesions was best for b1=800 s/mm
2 [29]. At
b1 valuesof100and,to a lesserextent,200s/mm
2theADC
values in hepatocellular carcinomas, metastases and hae-
mangiomas were elevated by perfusion contributions. This
compares with demonstrations that in normal liver and in
hepatocellular carcinoma at b=150 s/mm
2 the contribution
to the capillary flow to the signal attenuation is eliminated
[30, 31] and that the mean perfusion fractions in liver,
hepatocellular carcinoma, metastasis and haemangioma are
0.29,0.15,0.22and0.35,respectively[30].Inanotherstudy,
however, the ADC values in hepatocellular carcinoma,
hepatic metastases, cavernous haemangioma and hepatic
cystwerefoundtobeunaffectedatb1valuesof100,500and
1,000 s/mm
2, with decreasing spread of values at increasing
b1,indicatingthatthecalculatedADCvalueswouldbemost
accurate at the highest b1 value used [32]. The ADC of
hepatocellular carcinoma is slightly lower than ADC in
normal liver tissue, that of hepatic metastases was slightly
higher and the ADCs of cavernous haemangioma and
hepaticcystexceedtheADCofliverclearly[32,33].Here,it
is noted that whereas the diffusion properties of simple cysts
approximate those of free water, the ADC values of hydatid
hepatic cysts, containing structures such as a visible cyst
wall, multivesicular appearance, floating membranes or
calcification, tend to be slightly lower [34]. The closeness of
the ADC values of malignant lesions (hepatocellular carci-
noma,hepaticmetastases)tothoseofnormalliverunderlines
that the choice of b values is crucial in the detection of liver
tumours by DWI. This is illustrated by Fig. 3. The ADC
valueofcirrhoticlivertissueislowerthanthatofnormalliver
and the ADC of liver in patients with haemosiderosis is very
low [33]. Using b values up to 400 s/mm
2, higher liver and
cirrhotic liver ADC values were obtained than with b values
of up to 800 s/mm
2, whereas the significance of the
difference between liver and cirrhotic liver was highest at
2597the lower end of the range, an effect attributed to perfusion-
induced ADC increases in the normal liver measured at b<
400 s/mm
2 in particular [35]. The ADC of segment II,
anterior region, exceeds those measured in three other liver
segments and is less reproducible, probably because of the
increased exposure of segment II to cardiac motion artefacts
and the use of respiratory triggering [33]. Kwee at al.
recently reported that ADC measurements in respiratory-
triggeredDWIaresignificantlyhigherandless reproducible
than in breath-hold and free-breathing DWI [36]. Another
application of DWI is its use for control of treatment.
Different authors demonstrated a significant increase in
ADC from before to shortly after transcatheter arterial
chemoembolisation in large groups of patients with hepa-
tocellular carcinoma [37, 38], indicating that DWI could be
used as a predictor of the effectivity of treatment. The
location in liver can be a factor affecting the outcome of
DWI, although a recent study revealed that the ADC values
measured in segments V–VIII, right lobe, of the liver
parenchymaofpatients withbenignfocallesions,malignant
focal lesions and in patients without any lesions are very
similar [39]. TheADC values measured in fasted livers tend
to be lower than those in fed livers, probably because the
portal vein bulk increases significantly in all cases [40].
Fastingcouldthusbeofhelpinthediscriminationofhepatic
metastases (ADC slightly elevated) from liver parenchyma.
Viscoelasticity
Morphological criteria such as size, contour and shape are
usedinthediagnosisofdiffuseliverdisease.Changesinthese
measures occur late in the course of the disease, usually at an
irreversible stage. Alterations in stiffness can be assessed by
manual palpation, and more objectively by ultrasound (since
1990) [41] or MR elastography (MRE) (since 1995) [42, 43].
In MRE, the tissue’s constitutive parameters are visualised
byusingmotionencodingforimagingharmonicshearwaves
propagating in organs [42]. Shear waves are magnetically
encoded by bipolar gradients that usually oscillate with the
same frequency as the mechanical vibration. Liver fibrosis
can be detected by making wave images of a single
frequency from which the elastic and viscous moduli can
becalculated[44–47].InconventionalMREexperimentsthe
wave propagation speed and the wave-damping coefficient
can be deduced by repeatedly applying variable driving
frequencies. In a very simple model assuming that the
medium is nonviscous, the shear modulus or stiffness (μ)o f
the tissue examined can be defined as:
μ ¼ f λ ðÞ
2ρ (3)
The wavelength λ (in metres) visible on each phase
difference image isusedtocalculate μ,w h e r ef is the driving




c ADC map. The hepatocellular carcinoma insegmentIV (arrowhead)
shows a merely moderate signal loss from the b=50 s/mm
2 to the
b=600 s/mm
2 DW-SS-EPI image. The cyst in segment II (arrow)
displaysmarkedlyhighsignalintensityontheb=50s/mm
2DW-SS-EPI
image and becomes isointense on the b=600 s/mm
2 DW-SS-EPI
image. Onthe corresponding ADC map,the tumour shows a low ADC
value (1.18×10
−3 mm
2/s), whereas the cyst has a high ADC value
(3.09×10
−3 mm
2/s) (reproduced with permission from Bruegel et al.
[33])
2598cubic metre [44]. The frequency resolution of MRE data
gained can be entered into various models to obtain two,
three, or four independent constitutive parameters [48]. The
relatively simple Voight model has been used in the
characterisation of liver fibrosis because it fits the viscoelas-
tic parameters of soft materials well [49]. Here, the stress–
strain relationship is:
σ ¼ μ   ζδt ðÞ " (4)
withσthestrain,εthestress,μtheshearmodulus,ζtheshear
viscosity (attenuation within the medium) and δt the time-
derivative operator. For a homogeneous isotropic viscoelas-
tic medium, the complex modulus can then be related to
elasticity (μ) and viscosity (η)u s i n g :
GM ω ðÞ ¼ μ þ iωη (5)
Thisresults insix equations,three for the imaginary partand
three for the real part, to estimate the two unknown
viscoelastic parameters μ and η [48, 49].
A novel fast approach in MRE is to use broadband
frequencyencoding toacquiresuperposedtissue oscillations
at multiple frequencies rather than one frequency at a time
[48, 50]. This method is based on the increases in wave
propagation speed and the damping of shear waves in soft
tissue with the harmonic driving frequency as a result of the
dispersion (i.e. frequency dependence) of elastic waves in
viscous media.
Several studies, both single frequency MRE [44]a n d
multifrequency MRE [51], have shown that in high-grade
liver fibrosis viscosity and/or elastic moduli are significantly
elevatedcomparedwiththeresultsinhealthyvolunteers.Ina
recent large study of 96 patients suspected of having chronic
liver disease the elasticity was found to be significantly
elevated at histopathology METAVIR scores for fibrosis
higher than F1 [52]. Optimal cutoff values of elasticity were
2.5, 3.1 and 4.3 kPa for fibrosis scores greater than F1, F2
andF3,respectively[52].Systematicliverstiffnessincreases
with increased fibrosis stage of chronic liver disease were
also shown by others who examined 50 patients and
concluded that the predicted sensitivity and specificity for
detecting all grades of liver fibrosis was 98–99% [53]. In a
third study (of 44 patients) MRE of liver tumours revealed
significantly greater mean shear stiffness in malignant
tumours (10.1 kPa) compared with fibrotic liver (5.9 kPa),
benign tumours (2.7 kPa) and normal liver (2.3 kPa) [54].
This is illustrated by Fig. 4. A cutoff value of 5 kPa
differentiated benign tumours from malignant liver tumours.
The masses examined ranged from 1.4 to 11 cm in diameter,
but increasing tumour size, a factor expected to lead to
decreases in stiffness as necrosis-associated water and fat
contents increase, was not taken into account in this
preliminary study [54]. It is concluded that MRE appears
to be well suited to the noninvasive differentiation of
fibrotic liver and malignant liver tumours from normal
liver and benign lesions. According to a recent compre-
hensive review comparing different imaging modalities in
the diagnosis of hepatic fibrosis and cirrhosis, to date only
MRE has been able to stage fibrosis or diagnose mild
disease while ultrasonic elastography and DWI appear
next most promising [55].
Fig. 4 Patient with hepatic ad-
enoma. a T2-weighted MR
image shows hyperintense 8-cm
adenoma (arrow) in the right
lobe of the liver. b Gadolinium-
enhanced 3D spoiled gradient-
recalled echo MR image shows
intense arterial phase enhance-
ment (arrow). Washout was
evident in the portal venous
phase (not shown). c Axial MR
elastographic wave image
shows good illumination of the
tumour (circle). Waves in the
tumour have a slightly longer
length than those in the sur-
rounding normal liver paren-
chyma. d Elastogram with a
region of interest corresponding
to the tumour shows a shear
stiffness value of the tumour of
3.1 kPa and of the surrounding
liver of 2.4 kPa (reproduced
with permission from Venkatesh
et al. [54])
2599Fat content
Steatosis, the accumulation of fat in the liver, can lead to
fatty liver disease (steatohepatitis and cirrhosis) [56, 57].
The prevalence of steatosis (liver fat greater than 5% [58])
ranges from 30 to 34% [59–62] and is an early marker of
cardiovascular disease [62]. Liver fat contents under 20%
are required for donor livers [63]. Among current MRI
methods for quantifying liver fat content [64], single-voxel
MR spectroscopy (MRS) has become the gold standard
owing to the demonstration of high correlations with
pathological analysis of liver samples [65, 66]. Localized
MRS is based on spin-echo sequences and must therefore
be corrected for the T2 relaxation of the water and fat
signals (which may vary amongst different tissues), and
also for T1 relaxation if a short TR is used. Even properly
performed single-voxel MRS yields information about one
volume only, rendering the method nearly as irreproducible
as analysis of biopsies. Recently, we adapted multivoxel
MRS for the determination of reproducible hepatic fat
contents in volunteers and patients [67, 68]. This
possibility of determining the water-to-fat contents for an
array of voxels, yielding the average liver fat content with
the standard deviation being a measure of heterogeneity, is
illustrated by Fig. 5. Although MRS measurements of liver
fat content are performed without suppression of the water
signal, an additional water-suppressed measurement can be
used to assess the composition of the fatty acid chains by
focusing on the minor signals of the methene, diallylic,
methylene to carboxyl, and allylic groups [69]. This can
lead to improved understanding and management of fatty
liver disorders.
MRI methods for quantification of liver fat content are
faster, though, and therefore recommendable for use in
clinical practice. Those in most widespread use are based
on Dixon’s two-point technique [70], for instance, a breath-
hold gradient echo dual flip angle adaptation to generate
intermediate-weighted and T1-weighted opposed-phase
and in-phase images from which tissue fat contents can
be calculated [71]. Even after taking precautions to prevent
occasional mix-ups of water and fat signals, the MRI fat
determinations tend to overestimate liver fat content by up
to 4%, especially at the lower end of the range encountered
in most healthy individuals (fat content less than 10%)
[68]. The correlation between MRI and MRS data is strong,
however, so the systematic error in MRI measurements can
be corrected for [68]. Others have proposed variations in
the Dixon method using either three or more acquisitions
rather than two. In one of these studies, using seven echoes,
excellent correspondence was found between liver fat
contents according to MRI and MRS [72]; however, as
pointed out elsewhere [73], at the TR of 2,500 ms—the
only one used—the spectral water signals were saturated
relative to the fat (T1water≫T1fat). The resulting uncorrected
systematic overestimation of liver fat in the MRS data
implies that the closely matched MRI fat contents reported
Fig. 5 The volume of interest (a), spectral map (b) and a curve
fitted spectrum (c) of a healthy (obese) volunteer. The water and fat
peaks in the 32 quantified voxels yield a liver fat content, i.e. the
ratio of fat/(water + fat), of 21.3±5.5%. Unlike single-voxel MRS
giving a single value, multivoxel MRS provides a mean with a
standard deviation, the latter being a measure of tissue heterogeneity
(unpublished material from a study by Irwan et al. [68])
2600by O’Regan are also overestimated, especially at the lower
end of the range where the MRI contents already exceeded
the MRS fat contents by 0.2–1.1%. Another recent
modification is the sampling of the water and fat signals
at in-phase and partially opposed-phase acquisition,
meaning that the second image is acquired at a sampling
angle not equal to 180° [74]. Similar to the quadrature
sampling method [75–77] and direct phase encoding [78],
water and fat are separated as well as identified using the
lagging phase relationship [74].
An alternative MRI method that is possibly more precise
(with only small systematic error), is the slice-selective
gradient echo technique with spectral-spatial excitation
[79, 80]. In fat-selective MRI the fat contents are typically
calculated directly, i.e. after the appropriate corrections,
from a water-saturated single slab fat image in which the
signal intensities of liver tissue and subcutaneous fat are
compared. In phantom measurements the fat contents were
shown to be highly reproducible and well correlated with
the results of optical image analysis [79]. On the other
hand, because of the signal-to-noise ratio of the images, the
detection threshold in vivo was assessed to be as high as
2% of volume [80]. All of the above MRI methods will
work if T1 and T2* relaxation are corrected for, but will
become less reproducible in the case of very short T2* due
to, for example, iron overload. Overall, it appears that the
Dixon-based MRI techniques for determining liver fat
content currently are more reliable and robust than other
methods, and thus recommended for routine clinical
application.
Metabolism (MR spectroscopy)
In MRS nuclei other than hydrogen, such as phosphorus
(
31P) and carbon (
13C), are hampered by sensitivity (
31P,
13C) and natural abundance (
13C) [81]. Hydrogen (
1H,
proton) has the highest sensitivity of all radiofrequency
excitable nuclei and is therefore most suited to be studied in
MRS, especially on low-field MRI systems. However,
1H
MRS detection of tissue metabolites such as choline-
containing compounds (Cho) and creatine/phosphocreatine
(Cr) at concentrations near 1 mM requires effective
suppression of the abundant water and fat signals. For
that reason, phosphorus (
31P) MRS detection of phosphate
metabolites (phosphomonoesters, PME; inorganic phos-
phate, Pi; phosphodiesters, PDE; phosphocreatine, PCr;
and adenosine triphosphate, ATP, including the signals of
its analogues UTP, GTP and CTP), has been performed in
most human liver studies published to date. It should be
noted here that because of their extremely small T2
relaxation times large molecules, such as those present in
membranes, proteins, bone and DNA, do not contribute to
clinical MR spectra. The acquisition and postprocessing
methods, in particular how to quantify the peak areas of
overlapping metabolite signals, are critical. This leads to
discrepancies between studies, even in healthy controls
[82–84]. For example, in clinical practice one has to
compromise between the degree of T1 saturation as a result
of large pulse angles and short repetition times (TR) on the
one hand, and the signal-to-noise-ratio obtained on the
other [85, 86]. Even when high-field MRI equipment and/
or advanced techniques such as nuclear Overhauser effect
enhancement and proton decoupling are used [87, 88],
resulting in improved signal-to-noise ratios and better
spectral resolution between peaks, the spatial resolution
between adjacent MRS voxels should be to the order of a
centimetre to allow for the detection of low-concentration
metabolites.
Liver MRS studies focus on the status of the liver as a
whole or on the characterisation of focal hepatic lesions. In
the latter category of MRS studies one obviously wants to
be able to measure MRS voxels smaller than the lesions of
interest.
Diffuse liver disease
Phosphorus MRS Several large studies feature the use of
31P MRS for studying the metabolic alterations in chronic
liver disease, a disease caused by alcohol abuse, primary
biliary cirrhosis, virus infections, primary sclerosing
cholangitis etc. (Fig. 6). Cirrhotic patients have increased
levels of PME [89, 90] and decreased PDE [91].
Correlations of the PME/PDE ratio with the results of
liver biopsy [92] and with the degree of fibrosis [93]
indicate that
31P MRS can be used for staging and grading
of chronic liver disease. Decreases in PME/PDE were
observed in response to antiviral treatment for hepatitis C-
related liver disease [94]. Recently, however, it was shown
in a study of 80 cases of nonalcoholic fatty liver disease
that the observed elevations of PME relative to healthy
controls lost their significance when the results were
corrected for body weight [95]. Furthermore, patients
suffering from cachexia (body weight loss) as a result of
cancer elsewhere in the body had increased liver PME
levels and decreased ATP compared with weight-stable
cancer patients and healthy controls [96, 97]. Thus, host
body weight appears to be an underestimated factor with a
significant impact on
31P MR spectra of the liver, leading
to the requirement of body-weight-matched control
groups.
31P magnetisation transfer quantification of the
rate of ATP synthesis is developing into a new method of
liver characterisation [98]. Another new
31P MRS
application is the diagnosis of rejection after liver
transplantation. It was recently shown that chronic rejec-
tion (n=18) can be differentiated from good graft function




19F MRS Significant correlations between
liver glutamine/glutamate and Cho signals and the stage of
2601fibrosis in chronic hepatitis C patients [100] indicate that
proton MRS, already a widespread method for quantifying
liver fat content, will soon develop into a major line of
metabolic liver research. Natural abundance (i.e. 1.1%)
carbon-13 (
13C) MRS demonstration of the presence of
glycogen in the liver of a patient with glycogen storage
disease suggests that MRS could replace liver biopsy in
liver glycogen quantification [101]. Recently, others
showed correlations between fasting plasma glucose
level and both liver glycogen/glucose rate and liver
glycogen peak/fasting rate in diabetic patients, indicating
that
13C MRS can be used for noninvasive measurement of
glycogen storage/degradation ability in the liver and can
thus assist in tailor-made therapy for diabetes [102].
Another special feature is the use of fluorine-19 (
19F)
MRS as a means of quantifying 5-fluorouracil and related





31P MRS showed PME (fructose-1-phosphate)
increases and decreases in the levels of ATP and Pi in
healthy volunteers in response to bolus fructose adminis-
tration, whereas in three adults with disorders of fructose
metabolism no spectral changes were seen, providing proof
of fructokinase dysfunction [107]. In response to fructose
infusion, seven patients with nonalcoholic cirrhosis also
showed reductions in the formation of PME and in the
utilisation of Pi, thus providing metabolic evidence
confirming the expected impairment of liver function
[108]. Infusion of glucose, alanine and ATP caused modest
alterations in the levels of liver metabolites in cancer
patients with cachexia [109–111]. In normal liver, dietary
fish oil supplementation was shown to result in PDE
increases, indicating that lipid metabolism is influenced by
dietary intake [112].
Fig. 6 a {
1H}-
31P MRSI spectrum and corresponding hepatic
histology of a woman with alcoholic liver fibrosis. The biopsy
shows extensive periportal and parasinusoidal fibrosis in addition to
typical ballooning of hepatocytes. b {
1H}-
31P MRSI spectrum and
corresponding hepatic histology of a man with cirrhosis of the liver.
Biopsy shows micronodular alcoholic cirrhosis with typical
pseudolobules. Compared with spectra of healthy controls and the
patient with noncirrhotic liver disease increased PE/PC and,
compared with hepatocellular carcinoma, increased GPE/GPC ratios
can be observed. The position of the voxel observed is indicated in
orthogonal slices (reproduced with permission from Schlemmer et
al. [88])
2602Focal liver disease (
1H MRS)
The sensitivity and specificity of single-voxel
1H MRS in
diagnosing malignant hepatic tumours (n=53) were
reported to be less than 50% and 20%, respectively
[113], disappointing in view of ex vivo proton MRS results
showing that normal liver and cirrhotic liver were
distinguished from hepatocellular carcinoma (HCC) with
accuracies of 100% and 98%, respectively [114]. In
patients re-examined shortly after transcatheter arterial
chemoembolisation (TACE), reduced Cho and reduced
Cho/lipid ratios were observed in HCC [37, 114]. It may be
concluded that single-voxel MRS, while of use in tumour
follow-up, is not sufficiently robust for tumour character-
isation. One of the advantages in the use of multivoxel
MRS [67, 68] in tumour heterogeneity studies is the
possibility of retrospective positioning of the spectral map
over the tumour. Considering normal liver fat contents of
up to 5% [58], about two orders of magnitude higher than
Cho in malignant tumours, optimal multivoxel MRS of
liver tumours includes suppression of both lipid and water
signals. Previous single-voxel MRS studies lacked lipid
suppression [37, 113, 114]. In order to get direct
comparisons of voxels containing tumour and normal
liver tissue multivoxel MRS should be used, preferably
with fat suppression in order to improve the detection of the
millimolar range of metabolite signals (i.e. Cho in liver and
elevated Cho in tumour) in liver tissues containing at least
0.3% fat, even in healthy subjects [68]. Thus, with
incorporation of multivoxel MRS methods as well as
lipid suppression methods, MRS should soon develop into
a more successful method for the characterisation of liver
tumours than has been reported to date. The increasing
availability of high-field MR systems (3 T, 7 T…) will
enable future MRS studies to be performed faster and with
enhanced spatial resolution, the latter in particular of
interest in the study of small malignancies and tumour
heterogeneity.
Future prospects
In perfusion MRI a promising new application is thera-
peutic monitoring of antiangiogenic drugs in liver tumours.
The methods for quantifying liver iron content elevation, a
measure of inflammation, liver disease and cancer, already
appear to be optimised. It will be of interest to use the same
methods for monitoring iron accumulations in other organs
such as the heart. Because of the high perfusion fraction in
liver, the apparent diffusion coefficients strongly depend
on the gradient factors used in diffusion-weighted MRI.
While complicating analysis, this offers the opportunity to
study perfusion without contrast injection. Another novel
method, MRE, has already been established as the only
technique able to stage fibrosis or diagnose mild disease.
Further studies are needed to validate the possible
application of MRE in the diagnosis and monitoring of
cancer. The MRS and MRI methods for determining liver
fat content are already quite established and are expected to
become a major instrument in epidemiological studies of
populations increasingly suffering from overweight. Final-
ly, the implementation of multivoxel methods is expected
to greatly enhance the diagnostic value of MRS studies of
focal liver disease, in particular at high-field strengths.
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